Substance Use-Related Deaths Increased 64% Since 2001

Naomi Carr
Dr. David Miles
Written by Naomi Carr on 01 September 2026
Medically reviewed by Dr. David Miles on 02 September 2026

Substance use disorders can have many devastating impacts on individuals and communities. A recent analysis of CDC mortality data highlights how substance use and suicide mortality intersect and how their combined risks disproportionately affect certain communities, regions, and demographic groups.

Substance Use-Related Deaths Increased 64% Since 2001

Zhang et al. (2026) analyzed data compiled between 2001 and 2023 for the Centers for Disease Control and Prevention (CDC) WONDER Multiple Cause of Death database. Among deaths recorded during this timeframe, SUD-related suicide includes deaths with suicide listed as the underlying cause of death and substance use disorder (SUD) listed as one cause or contributing condition.

The following statistics were found:

  • Age-adjusted SUD-related suicide deaths increased by 64% between 2001 and 2023.
  • SUD-related suicide was highest among the age group 45-54 and lowest among 15-24.
  • Deaths were more than twice as high among men as among women throughout this period.
  • The proportionate rate of deaths among women increased much more rapidly in this period than among men, despite a larger number of male deaths overall.
  • There are significant disparities between certain demographic and geographic populations.

Substance use and suicide are significantly linked in various ways. Research has long linked substance use disorders to a substantial share of suicides (older reviews estimate between a quarter and half), and more recent meta-analyses find that people with a substance use disorder have roughly three times the suicide risk of the general population. Likewise, around 40% of people who accessed treatment for substance dependence report at least one attempted suicide.

The link between the two is complex and bidirectional. For example, both SUDs and suicide risk are associated with certain mental health symptoms and personality traits, including:

These factors can all be associated with an increased risk of suicidality and substance use, while also being exacerbated by both.

Role of opioids

Furthermore, the use of prescription or illicit opioids can influence suicidality drastically. For example:

  • The role of opioid prescriptions: The results of one study showed that suicide deaths are associated with opioid prescriptions, particularly high doses or long-term prescriptions. It also showed that regional decreases in opioid prescriptions were associated with declining numbers of suicide deaths.
  • The role of neurological and physical changes: Opioid or other substance dependence, whether prescribed or illicit, can be linked to suicidality, particularly in relation to withdrawal. SUDs, particularly OUD, can cause changes in the brain that could increase a person’s vulnerability to suicidal ideation and attempts.
  • Access to lethal means: Access to potent substances, like prescription opioids, also provides a means with which to attempt and complete suicide, further influencing this risk.

Which substances are most strongly associated with suicide risk

Alcohol and opioids are the most commonly associated substances with suicide risk, attempts, and mortality. This can be linked to:

Demographic and geographic disparities

Significant disparities were found among various demographic and geographic groups:

These disparities indicate a likelihood of socioeconomic, behavioral, and demographic influences on SUD-related suicide mortality. For example, the higher number of male deaths may be linked to substance use behaviors, the use of more lethal suicide methods, and social and structural barriers to mental health support.

What works: Prevention and treatment

Suicide risk can be significantly reduced with the implementation and maintenance of various interventions, including medications for OUD and professional substance use support.

For example, one study (Watts et al., 2022) of veterans found that stable OUD medication was associated with a 55% reduction in suicide mortality. Similarly, a study (Colledge-Frisby et al., 2023) found significantly reduced risks of self-harm and suicide among people on opioid agonist treatment (OAT), such as buprenorphine and methadone, for 29 days or more.

Both studies found that stable treatment was associated with lower risk, while stopping medications causes a rapid increase in risk.

Interventions such as these can improve suicide risk for various reasons, including:

  • Reducing cravings and emotional distress associated with addictive behaviors and physical dependence.
  • Buprenorphine blocks the kappa-opioid receptor, which researchers think may produce antidepressant and anxiety-reducing effects, though this is still an area of active study.
  • Therapeutic and psychosocial interventions can help reduce stressors and triggers associated with substance use and suicide risk, and improve early recognition and intervention.

What this means for communities and individuals

These findings imply that:

  • Certain communities and populations are at greater risk of substance-related suicide mortality.
  • Untreated or unmanaged SUDs significantly increase the risk of suicide.
  • Barriers to care, gender and population disparities, and limited resources can influence risks.

As such, managing substance-related suicide risk is complex and requires an individualized and integrated approach. Various factors can increase a person’s risk and should be recognized and managed through a range of professional and supportive approaches.

Implementing and maintaining SUD medications, providing psychological care, and improving psychosocial functioning can significantly reduce the risk of suicide mortality.

Final thoughts

This study demonstrates the growing issue of SUD-related suicide and emphasizes the need for integrated, comprehensive treatment approaches that recognize and address both risks concurrently. Implementing evidence-based treatment approaches, such as OAT, can be crucial for managing the neurological and biological impacts of substance use that directly contribute to increased suicide risk.

Furthermore, the significant demographic and geographic disparities highlighted in this study indicate a gap in current healthcare approaches. This requires targeted interventions and tailored support to promote early recognition and intervention in high-risk groups, reducing harm and saving lives.

Resources:

  1. Zhang, T., Shen, Y., Chen, Q., Du, J., & Hou, T. (2026). National trends, disparities and forecasts in substance use disorder-related suicide mortality in the United States: a CDC WONDER analysis. Frontiers in Public Health, 14, 1830159. Retrieved from
  2. Cavanagh, J.T., Carson, A.J., Sharpe, M., & Lawrie, S.M. (2003). Psychological autopsy studies of suicide: A systematic review. Psychological Medicine, 33(3), 395–405. Retrieved from
  3. Yuodelis-Flores, C., & Ries, R.K. (2015). Addiction and suicide: A review. The American Journal on Addictions, 24(2), 98–104. Retrieved from
  4. Rizk, M.M., Herzog, S., Dugad, S., & Stanley, B. (2021). Suicide Risk and Addiction: The Impact of Alcohol and Opioid Use Disorders. Current Addiction Reports, 8(2), 194–207. Retrieved from
  5. Olfson, M., Waidmann, T., King, M., Pancini, V., & Schoenbaum, M. (2023). Opioid Prescribing and Suicide Risk in the United States. The American Journal of Psychiatry, 180(6), 418–425. Retrieved from
  6. Watts, B.V., Gottlieb, D.J., Riblet, N.B., Gui, J., & Shiner, B. (2022). Association of Medication Treatment for Opioid Use Disorder With Suicide Mortality. The American Journal of Psychiatry, 179(4), 298–304. Retrieved from
  7. Colledge-Frisby, S., Jones, N., Degenhardt, L., Hickman, M., Padmanathan, P., Santo, T., Jr, Farrell, M., & Gisev, N. (2023). Incidence of suicide and self-harm among people with opioid use disorder and the impact of opioid agonist treatment: A retrospective data linkage study. Drug and Alcohol Dependence, 246, 109851. Retrieved from

Activity History - Last updated: 02 September 2026, Published date:


Reviewer

David is a seasoned Pharmacist, natural medicines expert, medical reviewer, and pastor. Earning his Doctorate from the Medical University of South Carolina, David received clinical training at several major hospital systems and has worked for various pharmacy chains over the years. His focus and passion has always been taking care of his patients by getting accurate information and thorough education to those who need it most. His motto: "Good Information = Good Outcomes".

Activity History - Medically Reviewed on 01 September 2026 and last checked on 02 September 2026

Medically reviewed by
Dr. David Miles

Dr. David Miles

PharmD

Reviewer

Recovered Branding BG
Ready to talk about treatment? Call today. (833) 840-1202
Helpline Information

Calls to numbers marked with (I) symbols will be answered or returned by one of the treatment providers listed in our Terms and Conditions, each of which is a paid advertiser.

In calling the helpline you agree to our Terms and Conditions. We do not receive any fee or commission dependent upon which treatment or provider a caller chooses.

There is no obligation to enter treatment.

Access State-Specific Provider Directories for detailed information on locating licensed service providers and recovery residences in your area.

For any specific questions please email us at info@recovered.org